| SLS161001 | Germline 3 Gene Panel | This test analyzes the BRCA1, BRCA2, and TP53 genes for mutations associated with hereditary cancer risks | Breast Cancer, Ovarian Cancer, Fallopian Tube Cancer, Prostate Cancer,Testicular Cancer, Pancreatic Cancer, Uterine Cancer, Cervical Cancer, Skin Cancer, Brain Cancer, Hematologic Cancer, Liver Cancer, Soft Tissue Sarcoma, Adrenal Cancer | | Hereditary Cancer Tests |
| SLS161000 | HBOC Basic Panel | This test detects mutations in the BRCA1 and BRCA2 genes, which are associated with hereditary breast and ovarian cancer | Breast Cancer, Ovarian Cancer, Fallopian Tube Cancer, Prostate Cancer,Testicular Cancer, Pancreatic Cancer, Uterine Cancer, Cervical Cancer, Skin Cancer, Brain Cancer, Hematologic Cancer | | Hereditary Cancer Tests |
| SLS161002 | HBOC Comprehensive Panel | This test screens for mutations in the BRCA1, BRCA2, PALB2, and TP53 genes, which are linked to hereditary breast and ovarian cancer | Hereditary Breast and Ovarian Cancer, Breast Cancer, Ovarian Cancer | | Hereditary Cancer Tests |
| SLS161003 | Germline BRCA1 & BRCA2 Test | This test evaluates mutations in 20 genes associated with hereditary breast and ovarian cancer | Hereditary Breast and Ovarian Cancer, Breast Cancer, Ovarian Cancer | | Hereditary Cancer Tests |
| SLS161004 | Lynch Syndrome Panel | This panel tests for mutations in 5 genes associated with Lynch syndrome | Colorectal Cancer, Endometrial Cancer, Stomach Cancer, Small Intestine Cancer, Ovarian Cancer, Kidney Cancer, Ureter Cancer, Pancreatic Cancer, Liver Cancer, Brain Cancer, Bladder Cancer, Prostate Cancer | | Hereditary Cancer Tests |
| SLS161005 | Germline Panel - Colorectal Cancer | This test analyzes 14 genes to assess the risk of hereditary colorectal cancer | Colorectal Cancer | | Hereditary Cancer Tests |
| SLS161006 | Germline Panel - Endocrine Cancer | This test covers 11 genes, which are associated with hereditary Endocrine Cancer | Endocrine Cancer | | Hereditary Cancer Tests |
| SLS161007 | Germline Panel - Renal Cancer | This test includes 7 genes linked to hereditary renal cancer | Renal Cancer | | Hereditary Cancer Tests |
| SLS161008 | Germline Panel - Prostate Cancer | This test evaluates 12 genes, for mutations associated with hereditary prostate cancer | Prostate Cancer | | Hereditary Cancer Tests |
| SLS161009 | Germline Panel - Nervous System Cancer | This test screens for mutations in 16 genes which are associated with hereditary nervous system cancer | Nervous System Cancer | | Hereditary Cancer Tests |
| SLS161010 | Germline Panel - Skin Cancer | This test covers 10 genes which are linked to hereditary skin cancer | Skin Cancer | | Hereditary Cancer Tests |
| SLS161011 | Germline Panel - Pancreatic Cancer | This test includes 14 genes associated with hereditary pancreatic cancer | Pancreatic Cancer | | Hereditary Cancer Tests |
| SLS161012 | Germline Panel - Gynaecological Cancer | This test analyzes 12 genes, for mutations linked to hereditary gynecological cancer | Breast Cancer, Ovarian Cancer, Fallopian Tube Cancer, Cervical Cancer, Skin Cancer | | Hereditary Cancer Tests |
| SLS161013 | Hereditary Cancer Test | This comprehensive test evaluates 36 genes associated with hereditary cancer syndromes across multiple organ systems, including ACMG recommended genes | All Hereditary Cancers, Breast Cancer, Ovarian Cancer, Prostate Cancer, Pancreatic Cancer, Uterine Cancer (Endometrial Cancer), Skin Cancer, Brain Cancer, Hematologic Cancer, Liver Cancer, Soft Tissue Sarcoma, Lung Cancer, Adrenal Cancer, Stomach Cancer, Colorectal Cancer | | Hereditary Cancer Tests |
| SLS161016 | Hereditary Cancer Test - RAPID | This test is a rapid version of the hereditary cancer test, analyzing 35 genes for hereditary cancer syndromes, including ACMG recommended genes | All Hereditary Cancers, Breast Cancer, Ovarian Cancer, Prostate Cancer, Pancreatic Cancer, Uterine Cancer (Endometrial Cancer), Skin Cancer, Brain Cancer, Hematologic Cancer, Liver Cancer, Soft Tissue Sarcoma, Lung Cancer, Adrenal Cancer, Stomach Cancer, Colorectal Cancer | | Hereditary Cancer Tests |
| SLS161014 | Germline Homologous Recombination Repair Test (HRR) | This germline test analyzes 14 genes involved in homologous recombination repair pathways | Breast Cancer, Ovarian Cancer, Prostate Cancer, Pancreatic Cancer, Colorectal Cancer, Endometrial Cancer,
Gastric Cancer, Biliary Duct Cancer,Lung Cancer | | Hereditary Cancer Tests |
| SLS162200 | Somatic BRCA Test | This test detects mutations in BRCA1 and BRCA2 genes in tumor tissue for the identification of therapeutic targets | Breast Cancer, Ovarian Cancer, Fallopian Tube Cancer, Prostate Cancer,Testicular Cancer, Pancreatic Cancer, Uterine Cancer, Cervical Cancer, Skin Cancer, Brain Cancer, Hematologic Cancer | | Somatic Cancer Tests |
| SLS162800 | Somatic Homologous Recombination Repair Test (sHRR) | This test evaluates 19 genes involved in the somatic homologous recombination repair pathway | Breast Cancer, Ovarian Cancer, Prostate Cancer, Pancreatic Cancer, Colorectal Cancer, Endometrial Cancer, Gastric Cancer, Biliary Duct Cancer, Lung Cancer | | Somatic Cancer Tests |
| SLS162201 | Homologous Recombination Deficiency Test (HRD) | This test analyzes 19 genes in the HRR pathway (including BRCA1 & BRCA2) along with genomic instability to assess homologous recombination deficiency | Ovarian Cancer | | Somatic Cancer Tests |
| SLS162203 | Homologous Recombination Deficiency Test (HRD) - RAPID | This test is a rapid version of the HRD test that evaluates 19 HRR genes along with genomic instability | Ovarian Cancer | | Somatic Cancer Tests |
| SLS160005 | Homologous Recombination Deficiency Test Plus (HRD Plus) | This test analyzes both somatic and germline BRCA1 and BRCA2 genes along with genomic instability | Ovarian Cancer | | Somatic Cancer Tests |
| SLS140010 | EGFR (Tissue) | This test detects mutations in the EGFR gene (Exons 18, 19, 20, and 21), including the resistance mutation T790M | Lung Cancer, Colorectal Cancer, Head & Neck Cancer, Glioblastoma | | Somatic Cancer Tests |
| SLS140006 | EGFR (Liquid Biopsy) | This test identifies EGFR mutations in plasma, including T790M and common driver mutations like L858R and Del19 | Lung Cancer, Colorectal Cancer, Head & Neck Cancer, Glioblastoma | | Somatic Cancer Tests |
| SLS162400 | Lung Cancer Essential Panel | This panel tests for mutations in 7 genes using DNA sequencing and fusions in 6 genes using RNA sequencing | Lung Cancer | | Somatic Cancer Tests |
| SLS160001 | Lung Cancer Actionable Panel | his test evaluates the presence of PDL-1 along with mutations in 7 genes using DNA sequencing and fusions in 6 genes using RNA sequencing for lung cancer | Lung Cancer | | Somatic Cancer Tests |
| SLS160002 | Lung Cancer Comprehensive Panel | This comprehensive panel evaluates the presence of PDL-1 along with mutations in 14 genes using DNA sequencing and fusions in 6 genes using RNA sequencing for lung cancer | Lung Cancer | | Somatic Cancer Tests |
| SLS162600 | Colorectal Cancer Essential Panel | This panel evaluates 7 genes for mutations associated with colorectal cancer | Colorectal Cancer | | Somatic Cancer Tests |
| SLS160003 | Colorectal Cancer Actionable Panel | This test analyzes 7 genes associated with colorectal cancer along with Microsatellite Instability (MSI) by PCR | Colorectal Cancer | | Somatic Cancer Tests |
| SLS160004 | Colorectal Cancer Comprehensive Panel | This comprehensive panel evaluates 22 genes associated with colorectal cancer along with MSI by PCR | Colorectal Cancer | | Somatic Cancer Tests |
| SLS162900 | Endometrial Cancer Test | This test identifies mutations in dMMR genes, POLE, and TP53 for endometrial cancer | Endometrial Cancer | | Somatic Cancer Tests |
| SLS163000 | Thyroid Cancer Basic Panel | This panel tests for 6 genes which are associated with thyroid cancer | Thyroid Cancer | | Somatic Cancer Tests |
| SLS163001 | Thyroid Cancer Advance Panel | This advanced test analyzes mutations in 6 genes using DNA sequencing and fusions in 3 genes using RNA sequencing for thyroid cancer | Thyroid Cancer | | Somatic Cancer Tests |
| SLS162004 | Somatic Advantage 74 (DNA+RNA) | This panel evaluates mutations in 74 genes using DNA sequencing and fusions in 14 genes using RNA sequencing for targeted somatic cancer therapy | All Solid Tumors, Comprehensive Profiling, Comprehensive Profiling | | Somatic Cancer Tests |
| SLS162012 | Somatic Advantage 74 (DNA+RNA) (RAPID) | This test is a rapid version of the Somatic Advantage 74 Test. It evaluates mutations in 74 genes using DNA sequencing and fusions in 14 genes using RNA sequencing for targeted somatic cancer therapy | All Solid Tumors, Comprehensive Profiling | | Somatic Cancer Tests |
| SLS162005 | Somatic Advantage 74 Liquid Biopsy | This test evaluates mutations in 74 genes using DNA sequencing and fusions in 14 genes using RNA sequencing through a non-invasive liquid biopsy | All Solid Tumors, Comprehensive Profiling | | Somatic Cancer Tests |
| SLS162009 | Somatic Advantage 74 Liquid Biopsy- RAPID | This test is a rapid version of the Somatic Advantage 74 Liquid Biopsy. It evaluates mutations in 74 genes using DNA sequencing and fusions in 14 genes using RNA sequencing through a non-invasive liquid biopsy | All Solid Tumors, Comprehensive Profiling | | Somatic Cancer Tests |
| SLS162010 | Somatic Advantage 74 Duo | This test offers a dual evaluation (through tissue biopsy and liquid biopsy) of mutations in 74 genes using DNA sequencing and fusions in 14 genes using RNA sequencing for somatic cancer profiling | All Solid Tumors, Comprehensive Profiling | | Somatic Cancer Tests |
| SLS162011 | Somatic Advantage 74 Reflex | This test includes analysis of mutations in 74 genes using DNA sequencing and fusions in 14 genes using RNA sequencing using tissue biopsies; the results of these are reflexed into liquid biopsy analysis | All Solid Tumors, Comprehensive Profiling | | Somatic Cancer Tests |
| SLS162003 | Somatic Advantage 500 Advanced (DNA+RNA) | This comprehensive panel evaluates mutations in 523 genes using DNA sequencing and fusions in 55 genes using RNA sequencing; it also analyzes Tumor Mutation Burden (TMB) and MSI | All Solid Tumors, Comprehensive Profiling | | Somatic Cancer Tests |
| SLS162013 | Somatic Advantage 500 Advanced (DNA+RNA)- RAPID | This test is a rapid version of the Somatic Advantage 500 panel, and evaluates mutations in 523 genes using DNA sequencing and fusions in 55 genes using RNA sequencing; it also analyzes Tumor Mutation Burden (TMB) and MSI | All Solid Tumors, Comprehensive Profiling | | Somatic Cancer Tests |
| SLS162403 | Lung Cancer Essential Panel - LB | This test evaluates SNVs/CNVs/InDels and fusions in 11 genes associated with Lung Cancer from a minimally invasive blood sample | Lung Cancer | | Somatic Cancer Tests |
| SLS162601 | Colorectal Cancer Essential Panel - LB | This test evaluates SNVs/CNVs/InDels in 7 genes associated with Colorectal Cancer from a minimally invasive blood sample | Colorectal Cancer | | Somatic Cancer Tests |
| SLS162002 | Somatic Advantage 500 Standard (DNA+RNA) | This panel evaluates mutations in 523 genes using DNA sequencing and fusions in 55 genes using RNA sequencing; it also analyzes Tumor Mutation Burden (TMB) and Microsatellite Instability (MSI) | All Solid Tumors, Comprehensive Profiling | | Somatic Cancer Tests |
| SLS162015 | Somatic Advantage 500 Standard (DNA+RNA) (Rapid) | This test is a rapid version of the Somatic Advantage 500 Standard Panel. It evaluates mutations in 523 genes using DNA sequencing and fusions in 55 genes using RNA sequencing; it also analyzes Tumor Mutation Burden (TMB) and Microsatellite Instability (MSI) | All Solid Tumors, Comprehensive Profiling | | Somatic Cancer Tests |
| SLS162017 | Somatic Advantage 500 Advanced - Liquid Biopsy | This test is a minimally invasive solution for comprehensive molecular profiling. It evaluates mutations in 523 genes using DNA sequencing and fusions in 55 genes; it also analyzes Tumor Mutation Burden (TMB) and MSI | All Solid Tumors, Comprehensive Profiling | | Somatic Cancer Tests |
| SLS810010 | Breast Cancer Prognostification Panel | This test evaluates biomarkers such as ER, PR, HER-2/neu, and Ki67 for breast cancer prognosis | Breast Cancer | | Non NGS Specialty Test |
| SLS810011 | Final Diagnosis Panel | This panel provides sequential testing to determine the final diagnosis of cancer | All Solid Tumors | | Non NGS Specialty Test |
| SLS810001 | PDL-1 22C3 (Dako) | This test evaluates the expression of the PDL-1 biomarker using the 22C3 clone for immunotherapy with Keytruda (pembrolizumab) | NSCLC, All Solid Tumors | | Non NGS Specialty Test |
| SLS810004 | PDL-1 SP142 (Ventana) | This test uses the SP142 clone to determine PDL-1 expression levels for immunotherapy with Tecentriq (atezolizumab) | TNBC, Urothelial Carcinoma, NSCLC | | Non NGS Specialty Test |
| SLS810006 | PDL-1 SP263 (Ventana) | This test assesses PDL-1 expression using the SP263 clone for guiding immunotherapy with Tecentriq (atezolizumab) and Imfinzi (durvalumab) | NSCLC, Head and Neck Cancer, Bladder Cancer | | Non NGS Specialty Test |
| SLS810009 | MSI by IHC | This test evaluates MLH1, MSH2, MSH6, and PMS2 proteins for Microsatellite Instability (MSI) by IHC | Colorectal Cancer, Endometrial Cancer, Stomach Cancer, Ovarian Cancer, Kidney Cancer | | Non NGS Specialty Test |
| SLS140025 | MSI by PCR | This test assesses mutations in MMR genes for Microsatellite Instability (MSI) using PCR methodology | Colorectal cancer, Endometrial Cancer, Stomach Cancer, Ovarian Cancer, Kidney Cancer | | Non NGS Specialty Test |
| SLS810008 | Head & Neck Therapeutic Test | This test evaluates EGFR, P53, and P16 genes for mutations relevant to Head and Neck Cancer therapy | Head and Neck Cancer | | Non NGS Specialty Test |
| SLS810002 | Gastric HER-2 | This test detects HER-2/neu overexpression in Gastric Cancer for targeted therapy | Gastric Cancer | | Non NGS Specialty Test |
| SLS150001 | MST (Sanger Sequencing) | This test identifies specific gene variants using Sanger sequencing for mutation confirmation | All Cancers | | Non NGS Specialty Test |
| SLS140014 | MLPA BRCA1 | This test detects large genomic rearrangements in the BRCA1 gene using Multiplex Ligation-dependent Probe Amplification | Hereditary Breast and Ovarian Cancer | | Non NGS Specialty Test |
| SLS140015 | MLPA BRCA2 | This test evaluates large genomic rearrangements in the BRCA2 gene using Multiplex Ligation-dependent Probe Amplification | Hereditary Breast and Ovarian Cancer | | Non NGS Specialty Test |
| SLS140016 | MLPA CHEK2 | This test detects large genomic rearrangements in the CHEK2 gene using Multiplex Ligation-dependent Probe Amplification | Hereditary Breast and Ovarian Cancer | | Non NGS Specialty Test |
| SLS140017 | MLPA MLH1 | This test identifies large genomic rearrangements in the MLH1 gene using Multiplex Ligation-dependent Probe Amplification | Colorectal Cancer, Endometrial Cancer, Stomach Cancer, Small Intestine Cancer, Ovarian Cancer, Kidney Cancer, Ureter Cancer, Pancreatic Cancer, Liver Cancer, Brain Cancer, Bladder Cancer, Prostate Cancer | | Non NGS Specialty Test |
| SLS140018 | MLPA MSH2 | This test analyzes large genomic rearrangements in the MSH2 gene using Multiplex Ligation-dependent Probe Amplification | Colorectal Cancer, Endometrial Cancer, Stomach Cancer, Small Intestine Cancer, Ovarian Cancer, Kidney Cancer, Ureter Cancer, Pancreatic Cancer, Liver Cancer, Brain Cancer, Bladder Cancer, Prostate Cancer | | Non NGS Specialty Test |
| SLS140019 | MLPA TP53 | This test detects large genomic rearrangements in the TP53 gene using Multiplex Ligation-dependent Probe Amplification | Li-Fraumeni Syndrome | | Non NGS Specialty Test |
| SLS140023 | MLPA PMS2 | This test identifies large genomic rearrangements in the PMS2 gene using Multiplex Ligation-dependent Probe Amplification | Colorectal Cancer, Endometrial Cancer, Stomach Cancer, Small Intestine Cancer, Ovarian Cancer, Kidney Cancer, Ureter Cancer, Pancreatic Cancer, Liver Cancer, Brain Cancer, Bladder Cancer, Prostate Cancer | | Non NGS Specialty Test |
| SLS140024 | MLPA CYP21A2 | This test evaluates large genomic rearrangements in the CYP21A2 gene using Multiplex Ligation-dependent Probe Amplification | Colorectal Cancer | | Non NGS Specialty Test |
| SLS140001 | BCR-ABL Translocation - Quantitative | This test quantifies the BCR-ABL translocation, associated with Chronic Myeloid Leukemia | Chronic Myeloid Leukemia (CML) | | Hemato Oncology |
| SLS169000 | Strand HLA (Human Leukocyte Antigen) Typing- High Resolution (12/12 match) | This test provides high-resolution HLA typing for a 12/12 match, covering HLA-A, B, C, DRB1, DQB1, and DPB1 | Hematologic Cancers | | Hemato Oncology |
| SLS160032 | Hereditary Cancer Test Plus | This test includes capture-based NGS for 137 genes along with digital MLPA for 28 genes to detect genetic variants associated with inherited cancers, including several rare cancers | All Hereditary Cancers, Breast Cancer, Ovarian Cancer, Prostate Cancer, Pancreatic Cancer, Uterine Cancer (Endometrial Cancer), Skin Cancer, Brain Cancer, Hematologic Cancer, Liver Cancer, Soft Tissue Sarcoma, Lung Cancer, Adrenal Cancer, Stomach Cancer, Colorectal Cancer | | Hereditary Cancer Tests |
| SLS160033 | Hereditary Cancer Test Plus - RAPID | This rapid test includes capture-based NGS for 137 genes along with digital MLPA for 28 genes to detect genetic variants associated with inherited cancers, including several rare cancers — with an expedited turnaround time to enable timely clinical decision-making | All Hereditary Cancers | | Hereditary Cancer Tests |
| SLS164500 | Comprehensive Myeloid Panel | This test includes comprehensive DNA and RNA analysis of 66 genes, supporting oncologists in the diagnosis and prognostication of Myeloid Malignancies | Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS), Myeloproliferative Neoplasms (MPN), Chronic Myeloid Leukemia (CML), Chronic Myelomonocytic Leukemia (CMML), Juvenile Myelomonocytic Leukemia (JMML) | | Hemato Oncology |
| SLS840002 | BRAF V600 by PCR | This test detects the BRAF V600 mutation in blood samples, which is commonly associated with various cancers and can inform targeted therapy | Melanoma, Colorectal Cancer, Thyroid Cancer, Non-Small Cell Lung Cancer (NSCLC) | | Non NGS Specialty Tests |
| SLS840003 | JAK2 Mutation Analysis (V617F) by qPCR | This test identifies the JAK2 V617F mutation in blood, a key marker in diagnosing Myeloproliferative Neoplasms such as Polycythemia Vera and Essential Thrombocythemia | Myeloproliferative Neoplasms (PV, ET, PMF) | | Non NGS Specialty Tests |
| SLS840009 | KRAS gene analysis by PCR | This test detects mutations in the KRAS gene from FFPE tissue samples to support the diagnosis and personalized treatment of certain cancers | Colorectal Cancer, Pancreatic Cancer, NSCLC | | Non NGS Specialty Tests |
| SLS140020 | MLPA RB1 | This test detects deletions or duplications in the RB1 gene, which are associated with Retinoblastoma and other cancer predispositions | Retinoblastoma, Osteosarcoma | | Non NGS Specialty Tests |
| SLS140021 | MLPA NF1 | This test identifies large deletions or duplications in the NF1 gene, aiding in the diagnosis of Type 1 Neurofibromatosis | Type 1 Neurofibromatosis, Gliomas, Pheochromocytoma | | Non NGS Specialty Tests |
| SLS140022 | MLPA ATM | This test analyzes copy number changes in the ATM gene, which is linked to Ataxia-Telangiectasia and increased cancer risk | Breast cancer, Pancreatic Cancer, Lymphoid Cancers | | Non NGS Specialty Tests |
| SLS140029 | MLPA MECP2 | This test identifies deletions or duplications in the MECP2 gene, associated with Rett syndrome and related neurodevelopmental disorders | Breast Cancer | | Non NGS Specialty Tests |
| SLS840007 | KRAS, NRAS & BRAF BY PCR - Sequencing | This test detects mutations in the KRAS, NRAS, and BRAF genes from FFPE samples to guide targeted therapy in cancers such as Colorectal Cancer and Melanoma | Colorectal Cancer, Melanoma, NSCLC | | Non NGS Specialty Tests |
| SLS840011 | MPN Reflex Panel (BCR ABL Qualitative, Calreticulin, JAK-2 v617F, MPL) | This reflex panel detects mutations in BCR-ABL, CALR, JAK2 V617F, and MPL genes to aid in the diagnosis and classification of Myeloproliferative Neoplasms | Myeloproliferative Neoplasms (PV, ET, PMF, CML) | | Hemato Oncology |
| SLS840005 | GIST Theranostic Panel | This test identifies mutations in the C-kit and PDGFR genes in FFPE tissue samples to support diagnosis and therapy selection in Gastrointestinal Stromal Tumors | Gastrointestinal Stromal Tumors | | Non NGS Specialty Tests |
| SLS840004 | PML/RARA t(15:17) Gene Rearrangement Quantitative-PCR | This test quantifies the PML/RARA gene fusion in blood or bone marrow samples to diagnose and monitor Acute Promyelocytic Leukemia | Acute Promyelocytic Leukemia | | Hemato Oncology |
| SLS840013 | PIK3CA - Mutation by PCR | This test detects mutations in the PIK3CA gene from blood samples, which can inform targeted treatment strategies in certain cancers | Breast Cancer, Colorectal Cancer, Endometrial Cancer | | Non NGS Specialty Tests |
| SLS830001 | HER2/neu Amplification by FISH | This test determines HER2 gene amplification in FFPE tissue samples to guide treatment decisions in Breast and Gastric Cancers | Breast Cancer, Gastric Cancer | | Non NGS Specialty Tests |
| SLS830002 | C-Myc by FISH | This test detects C-Myc gene rearrangements or amplifications in FFPE samples, which are relevant in the diagnosis and prognosis of certain cancers | Lymphomas (e.g., Burkitt Lymphoma, DLBCL), Multiple Myeloma | | Hemato Oncology |
| SLS830003 | N-Myc by FISH | This test identifies N-Myc gene amplification in FFPE tissue, which is useful in risk stratification in Neuroblastomas | Neuroblastoma | | Hemato Oncology |
| SLS169001 | Digital MLPA | This test evaluates copy number variations across 27 genetic markers using digital MLPA technology on blood samples, aiding in the diagnosis of various genetic disorders | Hereditary Cancers | | Hereditary Cancer Tests |
